Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 85 posts found.

Dendreon wins Provenge authorisation

September 19, 2013
Research and Development, Sales and Marketing Dendreon, Provenge, prostate cancer

News
bms

Yervoy setback in prostate cancer

September 16, 2013
Research and Development, Sales and Marketing BMS, Yervoy, melanoma, prostate cancer

News

Prostate cancer drug Xtandi gets nod

April 26, 2013
Sales and Marketing Xtandi, Zytiga, prostate cancer

Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …

News

Dendreon slashes staff and closes facility

July 31, 2012
Manufacturing and Production, Sales and Marketing Dendreon, M&P, Provenge, prostate cancer

Cancer vaccine specialist Dendreon has said it will slash 600 jobs and close one of its three manufacturing facilities in …

News
screen_shot_2012-07-05_at_11

New chairman of the board for Dendreon

July 5, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dendreon, Provenge, johnson, prostate cancer

Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the …

Appointment
Zytiga image

Price cut sways NICE on Zytiga

May 16, 2012
Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer

NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance.  In its final guidance, the watchdog is recommending …

News

UK government invests in new radiotherapy treatment

April 16, 2012
Sales and Marketing Cancer, Photon beam therapy, Proton beam therapy, prostate cancer, radiotherapy

The government is to invest £250 million in a cutting-edge radiotherapy treatment that should benefit 1,500 cancer patients in the …

News

Algeta to co-promote Alpharadin in US

April 12, 2012
Sales and Marketing Algeta, Bayer, prostate cancer

Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …

News

FDA grants priority review for Sanofi cancer drug

April 5, 2012
Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer

The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Prostate cancer drug extends life after chemotherapy

March 29, 2012
Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer

Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …

News
Janssen's Zytiga

Janssen’s Zytiga launched in the UK

September 21, 2011
Sales and Marketing Zytiga, prostate cancer

Janssen’s new advanced prostate cancer treatment Zytiga has been launched in the UK. Zytiga (abiraterone acetate) has been shown in …

News
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011
Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …

News
Bayer

FDA fast tracks Bayer prostate cancer drug

August 23, 2011
Sales and Marketing Algeta, Alpharadin, Bayer, prostate cancer

Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …

News

Janssen’s prostate cancer drug gains European backing

July 26, 2011
Sales and Marketing Zytiga, prostate cancer

Janssen’s prostate cancer treatment Zytiga has been recommended by Europe’s CHMP, paving the way for possible third quarter launch. The …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023